Avalon GloboCare (ALBT) said Tuesday it received a notice of allowance from the China National Intellectual Property Administration for its patent application covering a technology designed to "enhance" the expansion, manufacturing, survival, and efficacy of chimeric antigen receptor, or CAR-T and CAR-natural killer cells.
The company said it co-developed the patent with Hong Kong-based Arbele.
Avalon GloboCare shares were up 7.3% in recent trading.
Price: 3.96, Change: +0.27, Percent Change: +7.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.